Last reviewed · How we verify
NCT07063043
Clinical Research on 68Ga-FAPI PET/CMR in Cardiovascular Diseases
trial in Cardiovascular Diseases (CVD) in 40 participants. Currently enrolling.
31 December 2028
Quick facts
| Lead sponsor | Shanghai East Hospital |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 40 |
| Start date | 1 December 2024 |
| Primary completion | 31 December 2028 |
| Estimated completion | 31 December 2028 |
| Sites | 1 location across China |
Conditions studied
- Cardiovascular Diseases (CVD) — all drugs for Cardiovascular Diseases (CVD) →
Sponsor
Shanghai East Hospital
Who can join
18 and older, any sex, with Cardiovascular Diseases (CVD). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
FAP-targeted PET imaging using 68Ga-FAPI enables early detection of myocardial fibrosis. Combined PET/CMR provides comprehensive cardiac assessment without extra radiation. This advanced imaging approach improves diagnosis and personalized treatment for better patient outcomes.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07063043
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cardiovascular Diseases (CVD)
Currently open trials in the same condition.
- NCT07133516 — A Multi-center Study on Artificial Intelligence-Based Quantitative Evaluation of Echocardiography · recruiting
- NCT07043166 — Cardiovascular-Kidney-Metabolic Syndrome in Shanghai Zicitizens · recruiting
- NCT07248371 — Validating Integrative Multi-omics Approaches in Metabolic Syndrome-related Diseases · recruiting
- NCT07025590 — Effect of Exercise on Tapering Antipsychotics in Patients With Psycho-cardiological Disease(EXTRA-study) · NA · recruiting
- NCT06903559 — Roxadustat's Effect on Heart, Nutrition, and Inflammation in Hemodialysis Patients · Phase 1, PHASE2 · recruiting
Other Shanghai East Hospital trials
Trials by the same sponsor.
- NCT07519161 — Pharmacological Intervention to Prevent NOAF After TAVR · NA · not yet recruiting
- NCT07516223 — MRI-Assisted Guidance for Non-Essential Tissue Sampling · NA · not yet recruiting
- NCT07279259 — Thrombolysis in Early Acute Ischemic Stroke Trial-Blood Pressure Management · Phase 2 · recruiting
- NCT07294495 — Effect of Henagliflozin on Myocardial Fibrosis in Non-Obstructive HCM: A Randomized, Double-Blind, Placebo-Controlled Tr · NA · not yet recruiting
- NCT07290816 — Effect of Non-invasive Neuromodulation on the Quality of Intestinal Cleansing · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07063043 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanghai East Hospital
- Last refreshed: 14 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07063043.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing